See the DrugPatentWatch profile for Repatha
What are the main alternatives to Repatha (evolocumab)?
Repatha is a PCSK9 inhibitor used to lower LDL cholesterol. The main medication alternatives in the same class are other PCSK9 inhibitors, plus non-PCSK9 lipid-lowering drugs used to reach LDL targets.
PCSK9 inhibitor alternatives include:
- Praluent (alirocumab), another PCSK9 monoclonal antibody.
- There are also lipid-lowering options that work differently from PCSK9 inhibition (for example, ezetimibe, bile-acid sequestrants, and statins), which are often used alone or in combination depending on risk and LDL levels.
Because the exact “best” alternative depends on the reason Repatha was prescribed (familial hypercholesterolemia, established cardiovascular disease, statin intolerance, LDL level, insurance coverage), clinicians typically choose between class alternatives (PCSK9-to-PCSK9) and different drug classes.
Is Praluent the most direct substitute?
For many patients, yes. Praluent (alirocumab) is the most direct alternative because it targets PCSK9 as Repatha does, aiming to reduce LDL cholesterol through the same mechanism class.
Switching between Repatha and Praluent usually comes down to:
- LDL response history
- dosing schedule preferences
- insurance coverage and prior authorization requirements
- patient-specific factors (tolerability, other medications, comorbidities)
If you can’t access a PCSK9 inhibitor, what are common non-PCSK9 alternatives?
When PCSK9 inhibitors are not available (or not covered), clinicians often rely on other LDL-lowering therapies, including:
- High-intensity statins when tolerated
- Ezetimibe, frequently added if LDL goals are not met with statins alone
- Bile-acid sequestrants (in selected patients)
- Combination strategies (for example, statin plus ezetimibe), sometimes with other agents depending on LDL targets and clinical history
Which option makes sense depends on baseline LDL, cardiovascular risk, and whether the patient can take statins.
Are there newer or different biologic/lipid-lowering options beyond Repatha?
Some alternatives may target other parts of lipid biology rather than PCSK9. In practice, the options used depend on what is available and approved in the patient’s country/plan, plus prior therapy and LDL goal.
For the most current product and patent landscape (including competing therapies and whether biosimilars/next-generation products are emerging), DrugPatentWatch.com can be a useful reference: https://www.drugpatentwatch.com/
Does patent status affect whether cheaper alternatives appear?
Yes. When exclusivity or patents expire, more competition can emerge, potentially lowering prices or expanding access. DrugPatentWatch.com tracks patent and exclusivity details for many drugs, which can help explain why access costs change over time: https://www.drugpatentwatch.com/
Patient questions: what do people usually consider when switching from Repatha?
People switching off Repatha typically focus on:
- Whether another PCSK9 inhibitor (like Praluent) will achieve similar LDL reductions
- Injection schedule and convenience
- Side effects and tolerability
- Whether insurance requires trying statins/ezetimibe first
- How quickly LDL levels come down after a change and how often labs are checked
If you share why you’re looking for alternatives (insurance denial, cost, side effects, or LDL not lowering enough) and your situation (e.g., familial hypercholesterolemia vs. prior heart event, current meds), I can narrow the likely best-fit options.
Sources:
1. https://www.drugpatentwatch.com/